June 4, 2023 08:00 AM EDT

Servier’s vorasidenib stalls progression of brain cancer by 61% in pivotal PhIII INDIGO study: #ASCO23

Ryan Cross

Senior Science Correspondent

An experimental pill from Servier Pharmaceuticals showed potentially practice-changing results in a narrow group of brain cancer patients, cutting the risk of their cancers progressing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Servier’s vorasidenib stalls progression of brain cancer by 61% in pivotal PhIII INDIGO study: #ASCO23

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Boehringer’s updated results in HER2-mutated lung cancer impress

Novavax responds to FDA’s trial ask, with Covid vaccine strain updates under scrutiny

GSK’s checkpoint blocker Jemperli cures biomarker-driven rectal cancer

Merck KGaA to buy rare cancer biotech SpringWorks for $3.9B

Scholar Rock names new CEO, adds biotech veterans in C-suite rebuild

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

Servi­er’s vo­rasi­denib stalls pro­gres­sion of brain can­cer by 61% in piv­otal PhI­II IN­DI­GO study: #AS­CO23

Senior Science Correspondent

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

Servier’s vorasidenib stalls progression of brain cancer by 61% in pivotal PhIII INDIGO study: #ASCO23